JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
Enrolling by invitation · NCT06882876 · Registry updated 2025-09-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Enrolling by invitation | Phase 1 | 2025-09-19 | NCT06882876 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Junshi Bioscience Co., Ltd. | 42 |
| Xiangya Hospital of Central South University | 162 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Xiangya Hospital | Changsha | China | 2 |